Timo Soeterik

153 MRI T-stage for LNI Risk Prediction SUPPLEMENTAL SECTION SUPPLEMENTARY TABLE S1. MRI protocols used at each hospital SAH CWH HGT Field of strength of magnet 3T 3T 3T Coils used? Body coil Body coil Pelvic coil Slice thickness 3mm 3mm 3mm For T2-weighted imaging, which planes were acquired? Axial, sagittal, coronal Axial, sagittal, coronal Axial, sagittal, coronal For DWI, the b-values, image sets analyses (e.g. high b-value image, ADC map, or both) B 50-400-800 and calculated B1400 and ADC map B 0-50-100-200- 250-800 and ADC map B 50-400-800 and calculated B1400 and ADC map Scoring system used (if different were used, indicate per year) PI-RADS v2 PI-RADS v2 PI-RADS v2 Experience of radiologists reporting prostate MRI in the period 2-5 years 6 years >5 years Intravenous administration? (dosage, type e.g. Gadolinium + manufacturer) Gadolinium 0.1 mmol/kg (Dotarem) Gadolinium 1.0 mg/kg intravenous (Dotarem) Gadolinium 0.1 mmol/kg (Dotarem) SUPPLEMENTARY TABLE S2. Model performance parameters after pooling for DRE T- and mpMRI T- stage MSKCC 2018 Briganti 2012 DRE T-stage mpMRI T-stage DRE T-stage mpMRI T-stage AUC (95% CI) 0.71 (0.70 – 0.72) 0.72 (0.71 – 0.73) 0.73 (0.72 – 0.74) 0.75 (0.74 – 0.76) Mean predicted probability (%) 24 30 21 27 Calibration slope 0.84 (0.71 – 0.99) 0.83 (0.69 – 0.95) 0.90 (0.77 – 1.02) 0.88 (0.76 – 1.00) Calibration intercept 0.08 (0.04 – 0.12) 0.04 (0 – 0.08) 0.10 (0.06 – 0.13) 0.05 (0 – 0.08) Scaled Brier score 0.13 (0.08 – 0.18) 0.14 (0.08 – 0.19) 0.13 (0.07 – 0.18) 0.18 (0.12 – 0.24) * Overall prevalence of LNI on final histopathological evaluation was 28%. 8